Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University of Rostock.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Rostock
ClinicalTrials.gov Identifier:
NCT00947908
First received: July 27, 2009
Last updated: January 12, 2010
Last verified: July 2009

July 27, 2009
January 12, 2010
June 2009
June 2010   (final data collection date for primary outcome measure)
Number of myeloid DC and plasmacytoid DC in peripheral blood [ Time Frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00947908 on ClinicalTrials.gov Archive Site
Surface molecule expression on myeloid DC and plasmacytoid DC [ Time Frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy
Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Hymenoptera Venom Allergy
Biological: Hymenoptera venom
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Experimental: A
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Intervention: Biological: Hymenoptera venom

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
June 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with diagnosed hymenoptera venom allergy
  • No previous treatments for hymenoptera venom allergy

Exclusion Criteria:

  • Treatment with immunosuppressive agents
  • Any malignant disease
  • Infections within 1 week prior to the initiation of the treatment
Both
16 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00947908
LO-0004
No
PD Dr. Marek Lommatzsch, University of Rostock
University of Rostock
Not Provided
Not Provided
University of Rostock
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP